Bio-Techne Corp Company Profile (NASDAQ:TECH)

About Bio-Techne Corp (NASDAQ:TECH)

Bio-Techne Corp logoBio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NASDAQ:TECH
  • CUSIP: 87837710
  • Web:
  • Market Cap: $4.6 billion
  • Outstanding Shares: 37,382,000
Average Prices:
  • 50 Day Moving Avg: $121.82
  • 200 Day Moving Avg: $114.44
  • 52 Week Range: $95.68 - $124.94
  • Trailing P/E Ratio: 60.76
  • Foreward P/E Ratio: 28.05
  • P/E Growth: 2.99
Sales & Book Value:
  • Annual Revenue: $563 million
  • Price / Sales: 8.18
  • Book Value: $25.42 per share
  • Price / Book: 4.84
  • Annual Dividend: $1.28
  • Dividend Yield: 1.1%
  • EBITDA: $186.35 million
  • Net Margins: 12.93%
  • Return on Equity: 14.19%
  • Return on Assets: 8.43%
  • Debt-to-Equity Ratio: 0.36%
  • Current Ratio: 2.57%
  • Quick Ratio: 2.12%
  • Average Volume: 142,644 shs.
  • Beta: 0.76
  • Short Ratio: 8.97

Frequently Asked Questions for Bio-Techne Corp (NASDAQ:TECH)

What is Bio-Techne Corp's stock symbol?

Bio-Techne Corp trades on the NASDAQ under the ticker symbol "TECH."

How often does Bio-Techne Corp pay dividends? What is the dividend yield for Bio-Techne Corp?

Bio-Techne Corp declared a quarterly dividend on Wednesday, August 9th. Shareholders of record on Friday, August 18th will be paid a dividend of $0.32 per share on Friday, September 1st. This represents a $1.28 dividend on an annualized basis and a yield of 1.04%. The ex-dividend date is Wednesday, August 16th. View Bio-Techne Corp's Dividend History.

How were Bio-Techne Corp's earnings last quarter?

Bio-Techne Corp (NASDAQ:TECH) released its earnings results on Tuesday, August, 8th. The company reported $1.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.99 by $0.10. The company had revenue of $156.60 million for the quarter, compared to the consensus estimate of $150.25 million. Bio-Techne Corp had a net margin of 12.93% and a return on equity of 14.19%. The business's quarterly revenue was up 16.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.92 earnings per share. View Bio-Techne Corp's Earnings History.

When will Bio-Techne Corp make its next earnings announcement?

Bio-Techne Corp is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Bio-Techne Corp.

Where is Bio-Techne Corp's stock going? Where will Bio-Techne Corp's stock price be in 2017?

5 equities research analysts have issued 12-month price targets for Bio-Techne Corp's stock. Their forecasts range from $122.00 to $132.00. On average, they expect Bio-Techne Corp's share price to reach $126.33 in the next twelve months. View Analyst Ratings for Bio-Techne Corp.

Who are some of Bio-Techne Corp's key competitors?

Who are Bio-Techne Corp's key executives?

Bio-Techne Corp's management team includes the folowing people:

  • Robert V. Baumgartner CPA, Independent Chairman of the Board
  • Charles R. Kummeth, President, Chief Executive Officer, Director
  • Roger C. Lucas Ph.D., Independent Vice Chairman of the Board
  • James T. Hippel, Chief Financial Officer, Senior Vice President
  • Brenda S. Furlow J.D., Senior Vice President, General Counsel, Secretary
  • David Eansor, Senior Vice President - Biotechnology
  • Robert Gavin, Senior Vice President-Protein Platforms
  • Kevin S. Gould, Senior Vice President-Clinical Controls
  • J. Fernando Bazan Ph.D., Chief Technology Officer
  • Charles A. Dinarello M.D., Independent Director

How do I buy Bio-Techne Corp stock?

Shares of Bio-Techne Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Techne Corp's stock price today?

One share of Bio-Techne Corp stock can currently be purchased for approximately $123.13.

MarketBeat Community Rating for Bio-Techne Corp (NASDAQ TECH)
Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  172 (Vote Underperform)
Total Votes:  284
MarketBeat's community ratings are surveys of what our community members think about Bio-Techne Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Bio-Techne Corp (NASDAQ:TECH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $126.33 (2.60% upside)
Consensus Price Target History for Bio-Techne Corp (NASDAQ:TECH)
Price Target History for Bio-Techne Corp (NASDAQ:TECH)
Analysts' Ratings History for Bio-Techne Corp (NASDAQ:TECH)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/30/2017Deutsche Bank AGSet Price TargetBuy$132.00MediumView Rating Details
7/13/2017Wells Fargo & CompanyInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
5/3/2017Citigroup Inc.Reiterated RatingBuy$115.00 -> $125.00LowView Rating Details
3/27/2017Janney Montgomery ScottDowngradeBuy -> NeutralHighView Rating Details
11/10/2016Leerink SwannInitiated CoverageOutperform$122.00N/AView Rating Details
8/18/2016Robert W. BairdBoost Price TargetOutperform$115.00 -> $116.00N/AView Rating Details
11/2/2015Craig HallumLower Price TargetBuy$125.00 -> $110.00N/AView Rating Details
10/29/2015StephensDowngradeOverweight -> Equal WeightN/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Bio-Techne Corp (NASDAQ:TECH)
Earnings by Quarter for Bio-Techne Corp (NASDAQ:TECH)
Earnings History by Quarter for Bio-Techne Corp (NASDAQ TECH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017$0.88N/AView Earnings Details
8/8/2017Q4 2017$0.99$1.09$150.25 million$156.60 millionViewListenView Earnings Details
5/2/2017Q3 2017$0.93$0.97$142.83 million$144.04 millionViewListenView Earnings Details
2/7/2017Q217$0.85$0.81$134.74 million$131.80 millionViewListenView Earnings Details
10/31/2016Q117$0.79$0.84$127.47 million$130.60 millionViewListenView Earnings Details
8/17/2016Q416$0.96$0.92$129.23 million$134.80 millionViewListenView Earnings Details
5/3/2016Q316$0.89$1.01$122.65 million$131.00 millionViewN/AView Earnings Details
2/2/2016Q216$0.82$0.88$118.59 million$120.90 millionViewN/AView Earnings Details
10/28/2015Q1$0.85$0.79$116.91 million$12.40 millionViewListenView Earnings Details
8/6/2015Q415$0.86$0.87$116.85 million$117.70 millionViewN/AView Earnings Details
5/5/2015Q315$0.91$0.86$119.30 million$114.20 millionViewN/AView Earnings Details
2/3/2015Q215$0.86$0.89$112.73 million$111.90 millionViewN/AView Earnings Details
10/28/2014Q115$0.87$0.85$108.65 million$108.50 millionViewN/AView Earnings Details
8/11/2014Q414$0.85$0.88$91.80 million$92.50 millionViewN/AView Earnings Details
4/28/2014Q314$0.89$0.94$92.50 million$95.60 millionViewN/AView Earnings Details
2/4/2014Q214$0.80$0.75$84.79 million$84.00 millionViewN/AView Earnings Details
10/29/2013Q114$0.80$0.83$82.36 million$85.70 millionViewN/AView Earnings Details
8/6/2013Q4 2013$0.83$0.82$79.71 million$79.50 millionViewN/AView Earnings Details
4/30/2013Q3 2013$0.90$0.88$84.00 million$81.00 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.77$0.74$76.40 million$75.10 millionViewN/AView Earnings Details
10/23/2012$0.79$0.75ViewN/AView Earnings Details
7/31/2012$0.85$0.80ViewN/AView Earnings Details
5/1/2012$0.89$0.90ViewN/AView Earnings Details
1/31/2012$0.79$0.76ViewN/AView Earnings Details
10/25/2011$0.84$0.81ViewN/AView Earnings Details
8/2/2011$0.76$0.76ViewN/AView Earnings Details
5/3/2011$0.80$0.84ViewN/AView Earnings Details
2/1/2011$0.68$0.71ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Bio-Techne Corp (NASDAQ:TECH)
2017 EPS Consensus Estimate: $3.49
2018 EPS Consensus Estimate: $3.76
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.76$0.81$0.78
Q2 20173$0.81$0.85$0.83
Q3 20173$0.90$0.96$0.93
Q4 20173$0.93$0.98$0.95
Q1 20181$0.88$0.88$0.88
Q2 20182$0.82$0.89$0.86
Q3 20181$0.98$0.98$0.98
Q4 20182$1.02$1.07$1.05
(Data provided by Zacks Investment Research)


Current Dividend Information for Bio-Techne Corp (NASDAQ:TECH)
Most Recent Dividend:9/1/2017
Annual Dividend:$1.28
Dividend Yield:1.04%
Payout Ratio:65.98% (Trailing 12 Months of Earnings)
32.08% (Based on This Year's Estimates)
29.16% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Bio-Techne Corp (NASDAQ:TECH)

Dividend History by Quarter for Bio-Techne Corp (NASDAQ TECH)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Bio-Techne Corp (NASDAQ:TECH)
Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 98.40%
Insider Trades by Quarter for Bio-Techne Corp (NASDAQ:TECH)
Institutional Ownership by Quarter for Bio-Techne Corp (NASDAQ:TECH)
Insider Trades by Quarter for Bio-Techne Corp (NASDAQ:TECH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/10/2017Roger C LucasDirectorSell100$121.96$12,196.00View SEC Filing  
9/8/2017Roger C LucasDirectorSell100$120.94$12,094.00View SEC Filing  
9/6/2017Karen A HolbrookDirectorSell1,059$121.73$128,912.07View SEC Filing  
8/10/2017Roger C LucasDirectorSell100$114.30$11,430.00View SEC Filing  
7/10/2017Roger C LucasDirectorSell100$116.86$11,686.00View SEC Filing  
6/9/2017Roger C LucasDirectorSell100$113.62$11,362.00View SEC Filing  
5/31/2017Charles A DinarelloDirectorSell5,000$111.37$556,850.00View SEC Filing  
5/25/2017Karen A HolbrookDirectorSell5,000$111.15$555,750.00View SEC Filing  
5/10/2017Roger C LucasDirectorSell100$110.59$11,059.00View SEC Filing  
4/10/2017Roger C LucasDirectorSell100$101.15$10,115.00View SEC Filing  
1/10/2017Roger C LucasDirectorSell100$103.57$10,357.00View SEC Filing  
11/29/2016Karen A HolbrookDirectorSell1,000$106.73$106,730.00View SEC Filing  
11/16/2016Roger C LucasDirectorSell100$105.75$10,575.00View SEC Filing  
9/21/2016Roger C LucasDirectorSell100$108.91$10,891.00View SEC Filing  
9/8/2016John L HigginsDirectorSell1,700$109.83$186,711.00View SEC Filing  
9/8/2016Kevin S. GouldSVPSell524$110.50$57,902.00View SEC Filing  
9/2/2016Robert V BaumgartnerDirectorSell6,467$107.17$693,068.39View SEC Filing  
8/24/2016Robert V BaumgartnerDirectorSell3,533$107.10$378,384.30View SEC Filing  
8/17/2016Roger C. LucasDirectorSell100$113.70$11,370.00View SEC Filing  
7/20/2016Roger C LucasDirectorSell100$111.03$11,103.00View SEC Filing  
6/15/2016Roger C LucasDirectorSell100$112.15$11,215.00View SEC Filing  
5/18/2016Roger C LucasDirectorSell100$102.53$10,253.00View SEC Filing  
5/9/2016Charles A DinarelloDirectorSell5,000$101.91$509,550.00View SEC Filing  
5/6/2016Roger C LucasDirectorSell500$100.24$50,120.00View SEC Filing  
4/20/2016Roger C LucasDirectorSell100$92.40$9,240.00View SEC Filing  
3/16/2016Roger C LucasDirectorSell100$92.90$9,290.00View SEC Filing  
2/5/2016Roger C. LucasDirectorSell5,000$83.68$418,400.00View SEC Filing  
8/13/2015Roger C LucasDirectorSell5,000$106.01$530,050.00View SEC Filing  
6/8/2015Randolph C SteerDirectorSell1,000$99.39$99,390.00View SEC Filing  
2/19/2015Howard V OconnellDirectorSell5,000$95.78$478,900.00View SEC Filing  
12/10/2014Karen A HolbrookDirectorSell1,000$92.40$92,400.00View SEC Filing  
12/9/2014Kevin J ReaganVPSell3,591$89.35$320,855.85View SEC Filing  
12/8/2014Charles A DinarelloDirectorSell3,000$90.44$271,320.00View SEC Filing  
8/14/2014Karen A HolbrookDirectorSell5,000$95.54$477,700.00View SEC Filing  
5/7/2014Howard OconnellDirectorSell5,000$91.00$455,000.00View SEC Filing  
3/4/2014Karen HolbrookDirectorSell5,000$89.83$449,150.00View SEC Filing  
2/27/2014Randolph SteerDirectorSell5,000$88.78$443,900.00View SEC Filing  
11/13/2013Randolph SteerDirectorSell15,000$86.20$1,293,000.00View SEC Filing  
11/8/2013Robert BaumgartnerDirectorSell10,000$87.00$870,000.00View SEC Filing  
11/4/2013Roger C LucasDirectorSell10,000$87.64$876,400.00View SEC Filing  
5/6/2013Howard V OconnellDirectorBuy2,361$65.00$153,465.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Bio-Techne Corp (NASDAQ:TECH)
Latest Headlines for Bio-Techne Corp (NASDAQ:TECH)
DateHeadline logoComparing Global Blood Therapeutics (GBT) and BIO-TECHNE Corp (TECH) - October 17 at 4:30 PM logoBio-Techne Reaches Analyst Target Price - October 14 at 8:33 AM logoRoger C. Lucas Sells 100 Shares of Bio-Techne Corp (TECH) Stock - October 12 at 7:50 PM logoBio-Techne Corp (TECH) Raised to "Buy" at Zacks Investment Research - October 11 at 1:32 PM logoBio-Techne Corp (TECH) Given Average Rating of "Buy" by Brokerages - October 11 at 8:49 AM logoETFs with exposure to Bio-Techne Corp. : October 10, 2017 - October 11 at 8:26 AM logoBio-Techne To Host Conference Call On October 31, 2017 To Announce First Quarter 2018 Financial Results - October 11 at 8:26 AM logoBio-Techne Corp. :TECH-US: Earnings Analysis: Q4, 2017 By the Numbers : October 9, 2017 - October 10 at 7:26 AM logoJoint Consortia Framework Awards Contract to Bio-Techne as Supplier of Research Antibodies - October 6 at 11:08 AM logoBio-Techne Corp (TECH) & Its Competitors Head-To-Head Comparison - October 4 at 8:36 AM logoBio-Techne's New Simple Plex Cartridge Boosts Protein Segment - October 3 at 1:26 PM logoBio-Techne Shows Rising Relative Strength; Still Shy Of Key Benchmark - October 3 at 1:26 PM logo$142.75 Million in Sales Expected for Bio-Techne Corp (TECH) This Quarter - October 2 at 5:18 AM logo Analysts Expect Bio-Techne Corp (TECH) Will Announce Earnings of $0.89 Per Share - September 30 at 2:20 PM logoBerkeley accelerator adds money to the mix - September 29 at 9:38 AM logoBio-Techne Unveils a New Multi-Analyte Cartridge Format for the Ella™ Immunoassay Platform, Improving Sample Throughput - September 20 at 9:50 AM logoBio-Techne Corp (TECH) Given Consensus Rating of "Buy" by Analysts - September 16 at 8:34 AM logoETFs with exposure to Bio-Techne Corp. : September 14, 2017 - September 14 at 11:05 AM logoBio-Techne CEO Charles Kummeth's compensation jumps to $9.1M - September 13 at 10:00 AM logoBio-Techne Introduces a New Luminex Multi-analyte Assay Kit - September 13 at 10:00 AM logoInsider Selling: Bio-Techne Corp (TECH) Director Sells 100 Shares of Stock - September 12 at 8:24 PM logoBio-Techne Corp. :TECH-US: Earnings Analysis: 2017 By the Numbers : September 11, 2017 - September 12 at 10:47 AM logoContrasting Bio-Techne Corp (TECH) and its Competitors - September 12 at 12:28 AM logoKaren A. Holbrook Sells 1,059 Shares of Bio-Techne Corp (TECH) Stock - September 8 at 8:40 PM logoFeatured Company News - Bio-Techne Acquires Trevigen in an All-cash Deal - September 8 at 9:12 AM logoBio-Techne Releases A Highly Sensitive and Specific Serological Assay to Detect Zika Virus Infections - September 7 at 9:46 AM logoBRIEF-Bio-Techne acquires Trevigen Inc - September 6 at 9:06 AM logoBio-Techne buys Trevigen in all-cash deal - September 6 at 7:35 AM logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bio-Techne Corporation - TECH - August 31 at 10:51 AM logoDeutsche Bank AG Reiterates $132.00 Price Target for Bio-Techne Corp (TECH) - August 30 at 10:34 PM logoBio-Techne To Present At The Wells Fargo Healthcare Conference - August 29 at 8:33 AM logo Brokerages Anticipate Bio-Techne Corp (TECH) Will Post Quarterly Sales of $142.75 Million - August 26 at 7:26 PM logoBio-Techne Corp to Post FY2019 Earnings of $3.99 Per Share, William Blair Forecasts (TECH) - August 23 at 3:22 PM logoBio-Techne To Present At The Baird 2017 Global Healthcare Conference - August 23 at 12:28 PM logoWilliam Blair Weighs in on Bio-Techne Corp's FY2018 Earnings (TECH) - August 22 at 1:58 PM logoBio-Techne Corp (TECH) Given Consensus Rating of "Hold" by Analysts - August 22 at 8:34 AM logoGoogle's Alphabet passes Facebook as hedge fund favorite - August 20 at 11:05 PM logoBio-Techne Corp. – Value Analysis (NASDAQ:TECH) : August 19, 2017 - August 19 at 8:09 AM logoCorporate News Blog - Exelixis Submits US Supplemental New Drug Application for CABOMETYX(R) for the Treatment of Previously Untreated Advanced Kidney Cancer - August 18 at 7:47 AM logoRoger C. Lucas Sells 100 Shares of Bio-Techne Corp (NASDAQ:TECH) Stock - August 15 at 12:16 AM logoBio-Techne Corp Forecasted to Post Q2 2018 Earnings of $0.82 Per Share (TECH) - August 14 at 7:38 AM logoSee what the IHS Markit Score report has to say about Bio-Techne Corp. - August 10 at 9:31 PM logoBio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4 - August 10 at 4:28 PM logoBio-Techne Corp Declares Quarterly Dividend of $0.32 (TECH) - August 10 at 2:20 PM logoBRIEF-Bio-Techne Q4 adjusted earnings per share $1.09 - August 10 at 8:40 AM logoBio-Techne Corp (TECH) PT Raised to $132.00 at Deutsche Bank AG - August 9 at 2:08 PM logoBio-Techne Releases Fourth Quarter Fiscal 2017 Results - August 9 at 8:08 AM logoBio-Techne Corp. breached its 50 day moving average in a Bullish Manner : TECH-US : August 8, 2017 - August 9 at 8:08 AM logoEdited Transcript of TECH earnings conference call or presentation 8-Aug-17 1:00pm GMT - August 9 at 8:08 AM logoBio-Techne Corp (NASDAQ:TECH) Issues Quarterly Earnings Results - August 8 at 1:52 PM



Bio-Techne Corp (TECH) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.